Please login to the form below
Ozurdex
This page shows the latest Ozurdex news and features for those working in and with pharma, biotech and healthcare.
NICE backs Bayer's Eylea in diabetic eye condition
TheInstitute also recommends Allergan's Ozurdex in final guidance. Bayer's Eylea and Allergan's Ozurdex have been recommended for use on the NHS in England to treat diabetic macular oedema ... Meanwhile, NICE also recommended the use of Allergan's
Latest news
-
NICE recommends Ozurdex for diabetic eye condition
The preliminary recommendations cite the implant, marketed by Allergan as Ozurdex, as a treatment option in patients where the implant is to be used in an eye with an intraocular (pseudophakic) ... Ozurdex is injected into the eye once every six months
-
Fresh approval for Roche's Lucentis as competition heats up
Roche's drug is being challenged in the market by Bayer's Eylea (aflibercept) as well as newer entrants such as Allergan's Ozurdex (intravitreal dexamethasone).
-
New eye indication for Allergan’s Ozurdex
The European Commission granted marketing authorisation to Ozurdex, an eye implant that contains the corticosteroid dexamethasone, as a treatment for adults with visual impairment due to diabetic macular oedema (DMO). ... Ozurdex joins a competitive
-
Allergan will start phase III DARPin trials next year
On the plus side, Allergan said the FDA had approved a new indication for its intravitreal implant Ozurdex (dexamethasone), namely the treatment of diabetic macular oedema (DME) in adults who have
-
NICE against new indication for Novartis' Lucentis
Its draft guidance concluded the ICER for Lucentis in central RVO versus Allergan's Ozurdex (dexamethasone) intravitreal implant, the currently approved treatment, was likely to be over £37, 400 per QALY ... Ozurdex was recommended by NICE earlier this
More from news
Approximately 3 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Allergan and taking a specialised approach
spasticity associated with stroke and for the ophthalmology treatment Ozurdex in diabetic macular oedema.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Account Director – UK Office
-
Excellent salary and benefits
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Account Director, Healthcare Communications
-
Salary TBC
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
